

07-06-02-

JFW



Please type a plus sign (+) inside this box →



PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1 style="text-align: center;">TRANSMITTAL FORM</h1> <p style="text-align: center;">(to be used for all correspondence after initial filing)</p>		Application Number	10/825,858
		Filing Date	April 16, 2004
		First Named Inventor	ANDERSON, RAYMOND
		Group Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	5	Attorney Docket Number	SMAR-036
ENCLOSURES (check all that apply)			
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement SB08a Form <input type="checkbox"/> Certified Copy of Priority Documents <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): 24 References Postcard	Remarks
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Signing Attorney/Agent (Reg. No.)	CAROL L. FRANCIS, 36.513 BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	July 2, 2004		
EXPRESS MAIL LABEL NO. EV 333997511 US			

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Express Mail No. EV 333997511 US

INFORMATION DISCLOSURE STATEMENT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450	Attorney Docket	SMAR-036
	First Named Inventor	ANDERSON, RAYMOND
	Application Number	10/825,858
	Confirmation No.	
	Filing Date	April 16, 2004
	Group Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
	Title:	"SHIP 1 MODULATORS"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. SMAR-036 may be charged thereon.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP


Date:

July 2, 2004

By:

Carol L. Francis
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



PTO/SB/08A (10-01)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	10/825,858
Filing Date	April 16, 2004
First Named Inventor	Raymond Andersen
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	SMAR-036

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	A1	US 6,238,903		05/29/2001	Krystal	
	A2	US				
	A3	US				
	A4	US				
	A5	US				
	A6	US				
	A7	US				
	A8	US				
	A9	US				
	A10	US				
	A11	US				
	A12	US				
	A13	US				
	A14	US				
	A15	US				
	A16	US				
	A17	US				
	A18	US				
	A19	US				
	A20	US				

FOREIGN PATENT DOCUMENTS


Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	B1	WO	03033517	04/24/2003	The University of British Columbia		
	B2						
	B3						
	B4						
	B5						
	B6						
	B7						
	B8						

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	10/825,858
Filing Date	April 16, 2004
First Named Inventor	Raymond Andersen
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	SMAR-036

OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Boreham, Christopher J., et al., "Structure and origin of the two major monoaromatic hydrocarbons in a tasmanite oil shale from Tasmania, Australia," Organic Geochemistry (1995) 23(5):461-6.	
	C2	Corey, Elias J., et al., "Exceptionally simple enantioselective syntheses of chiral hexa- and tetracyclic polyprenoids of sedimentary origin," Angewandte Chemie, Intl. Ed. (1998) 37(8):1126-1128.	
	C3	Damen, J.E., et al., "Multiple forms of the SH2-containing inositol phosphatase, SHIP, are generated by c-terminal truncation," Blood (1998) 92(4):1199.	
	C4	Database CA 'Online! Sorokina, I.B., et al. "Estrogen and antineoplastic activity in a series of transformed estrone and estradiol analogs," Izvestiya Akademii Nauk SSSR, Seriya Biologicheskaya (1973), vol. 5, pgs. 664-70, CODENL IANBAM; 0002-3329, Database accession no. 80:91450. (Document No. XP002230773)	
	C5	Freeman, Katherine H., et al., "The effect of aromatization on the isotopic compositions of hydrocarbons during early diagenesis," Organic Geochemistry (1994) 21(10-11):1037-1049.	
	C6	Goclik, Eva, et al., "Pelerol from the tropical Marine Sponge Dactylospongia elegans," Journal of Natural Products (2000), 63:8, 1150-1152. (Document No. XP002254980)	
	C7	Harring, Scott, et al., "Polyene cascade cyclizations mediate by BF ₃ ·OEt ₂ ·CH ₃ NO ₂ . An unusually efficient method of polycyclic intermediates via cationic initiations at non-functionalized 3 alkenes. An application to the total synthesis of (racemic)-taxodione," Tetrahedron, (1994) 50:31, 9229-9254 (Document No. XP002230772)	
	C8	He, W, et al., "Novel cytokine release inhibitors. Part III: truncated analogs of tripterine," Bioorganic & Medicinal Chemistry Letters, Oxford, BG (1998) 8:24, 3659-3664.	
	C9	Helgason, C.D., et al., "Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span," Genes Dev. (1998) 12:1610-1620.	
	C10	Helgason, C.D., et al., "A dual role for src homology 2 domain-containing inositol-5-phosphatase (SHIP) in immunity: aberrant development and enhanced function of b lymphocytes in SHIP ^{-/-} mice," J. Exp. Med. (2000) 191(5):781-794.	
	C11	Herz, Werner, et al., "Resin Acids. XV. Oxidative transformations of the levopimaric acid-acetylenedicarboxylic ester adduct," Resin Acids. (1969) 34(5):1257-1266.	
	C12	Huber, M., et al., "The role of SHIP in growth factor induced signaling," Prog Biophys Mol Biol. (1999) 71(3-4) 423-34.	
	C13	Ishihara, Kazuaki, et al., "Enantioselective biomimetic cyclization of homo-polyprenyl0arens. A new entry to (+)-podcarpa-8,11,13-triene diterpenoids and (-)-tetracyclic polyprenoid of sedimentary origin," J. of the American Chem. Soc. (2001) 123:1505-1506.	
	C14	Ishihara, Kazuaki, et al., "Enantio- and diastereoselective stepwise cyclization of polyprenoids induced by chiral and achiral LBAs. A new entry to (-)-ambrox, (+)-podcarpa-8,11,13-triene diterpenoids, and (-)-tetracyclic polyprenoid of sedimentary origin," J. of the American Chem. Soc. (2002) 124:3647-3655.	


Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

Complete if Known

Application Number	10/825,858
Filing Date	April 16, 2004
First Named Inventor	Raymond Andersen
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	SMAR-036

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C15	Kwak, J.H., et al., "Sesquiterpene quinols/quinones from the micronesian sponge petrosaspongia metachromia," J. Nat. Prod. (2000) 63(8):1153-56.	
	C16	Liu, Ling, et al., "A specific inhibitor of SH2-containing inositol-5-phosphatase (SHIP)," (2001) Blood 98:1225 LY288975 (Abstract No. 1225).	
	C17	Mitome, Hidemichi, et al., "Dactyloquinones a and B, new sesquiterpenoid quinones from the okinawan marine sponge <i>Dactylospongia elegans</i> ," J. Nat. Prod. (2001) 64:1506-1508.	
	C18	Mitome, Hidemichi, et al., "Dactyloquinones c, d and e novel sesquiterpenoid quinones, from the okinawa marine sponge, <i>Dactylospongia elegans</i> ," Tetrahedron (2002) 58:1693-1696.	
	C19	Mukku, Venugopal J.R., et al., "New sesquiterpene quinols from a micronesian sponge, <i>aka</i> sp," J. Nat. Prod. (2003) 66:686-689.	
	C20	O'Farrell, A.M. et al., "Stat3-dependent induction of p19 ^{ink4d} by il-10 contributes to inhibition of macrophage proliferation ¹ ," J. Immunol (2000) 164:4607-4615.	
	C21	Rosales, Viale, et al., "Regioselective palladium-catalyzed alkylation of allylic halides with benzylic grignard reagents. Two-step synthesis of abietane terpenes and tetracyclic polyprenoid compounds," J. of Organic Biochem (2002) 67(4):1167-1170.	
	C22	Sattler, M., et al., "BCR/ABL directly inhibits expression of SHIP, an SH2-containing polyinositol-5-phosphatase involved in the regulation of hematopoiesis," Mol Cell Biol (1999) 19(11):7473-7480.	
	C23	Schaeffer, Phillippe, et al., "Novel optically active hydrocarbons in sediments: evidence for an extensive biological cyclization of higher regular polyprenols," Angew. Chem. Int. Ed. Engl. (1994) 33(11):1166-1169 (Angew. Chem. (1994) 106:1235-8).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.